I-Mab (IMAB) Stock Forecast & Price Target

I-MAB's drug pipeline, particularly Givastomig, demonstrates a promising clinical profile with an emerging widened therapeutic index in comparison to existing CLDN18.2-targeted therapies. The recent data updates indicate a positive trend in the overall response rate (ORR), with an increase from 16% to 18%, suggesting effective patient outcomes as more data becomes available. Furthermore, the renewed focus on targeting 4-1BB in immunotherapy reflects a significant interest and potential growth in this area, positioning I-MAB advantageously within the biotech sector.

I-MAB faces a challenging outlook due to persistent safety and efficacy concerns related to its first-generation 4-1BB agonist antibodies, particularly regarding on-target off-tumor hepatotoxicity. Although the incidence of Grade 3+ treatment-related adverse events (TRAEs) for Givastomig was reported at 24%—lower than competitors such as AZD0901 and Tecotat vedotin—the overall safety profile remains a significant risk that could hinder clinical development and potential market acceptance. Additionally, discrepancies in patient performance between Western and Asian demographics further complicate cross-trial comparisons, raising additional uncertainties about the generalizability of trial results and the long-term viability of I-MAB’s drug pipeline.